Exchange: NASDAQ·Updated 07:58 PM EST

ALDX News

News
all
press releases
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week
Ultragenyx agrees to sell its Fayuvi-linked PRV for $203 million, marking its second voucher sale in one week and adding non-dilutive funding for rare-disease programs.
Zacks
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week
Ultragenyx agrees to sell its Fayuvi-linked PRV for $203 million, marking its second voucher sale in one week and adding non-dilutive funding for rare-disease programs.
Zacks
More News
Alto advances its depression drug pipeline, with key 2027 study results ahead for ALTO-207, ALTO-300 and ALTO-100.
Zacks
SNDX shares plunge 16% as its phase II axatilimab study misses the primary endpoint, prompting the company to abandon development in idiopathic pulmonary fibrosis.
Zacks
PRME shares jump nearly 26% in a month as FDA clearance for PM647 and PM577a's clinical debut advances its gene-editing pipeline.
Zacks
PMV Pharmaceuticals gains on promising rezatapopt data in ovarian cancer, FDA support for accelerated approval and a planned 2027 NDA filing.
Zacks
ARGX's FB102 achieves its primary endpoint in a phase II celiac disease study, paving the way for late-stage development despite a nearly 12% stock drop.
Zacks
Editas Medicine gains approval to launch the first-in-human phase I/II study of EDIT-401 in Australia, targeting LDL cholesterol through gene editing.
Zacks
Lipocine's Tlando royalties, Brlizio's phase III trial and broader pipeline offer multiple potential growth drivers and catalysts.
Zacks
RARE enters into an agreement to sell a Rare Pediatric Disease PRV for $210M, adding non-dilutive cash as it advances rare-disease therapies.
Zacks
Eton's sales surge, raised 2026 outlook and expanding rare-disease portfolio are boosting confidence in its growth.
Zacks

Advertisement|Remove ads.